Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.

导出 LinkOut

翻译打印收藏纠错

作者： Cynthia X,Ma ^[1] ; Vera J,Suman ^[2] ; Souzan,Sanati ^[3] ; Kiran,Vij ^[1] ; Meenakshi,Anurag ^[4] ; A Marilyn,Leitch ^[5] ; Gary W,Unzeitig ^[6] ; Jeremy,Hoog ^[1] ; Aranzazu,Fernandez-Martinez ^[7] ; Cheng,Fan ^[7] ; Richard A,Gibbs ^[4] ; Mark A,Watson ^[1] ; Travis J,Dockter ^[2] ; Olwen,Hahn ^[8] ; Joseph M,Guenther ^[9] ; Abigail,Caudle ^[10] ; Erika,Crouch ^[1] ; Amy,Tiersten ^[11] ; Monica,Mita ^[3] ; Wajeeha,Razaq ^[12] ; Tina J,Hieken ^[13] ; Yang,Wang ^[14] ; Mothaffar F,Rimawi ^[4] ; Anna,Weiss ^[15] ; Eric P,Winer ^[16] ; Kelly K,Hunt ^[10] ; Charles M,Perou ^[7] ; Matthew J,Ellis ^[4] ; Ann H,Partridge ^[17] ; Lisa A,Carey ^[7]

作者单位： Washington University School of Medicine, St Louis, Missouri. ^[1] Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota. ^[2] Cedars-Sinai Medical Center, Los Angeles, California. ^[3] Baylor College of Medicine, Houston, Texas. ^[4] University of Texas Southwestern Medical Center, Dallas. ^[5] Doctor's Hospital of Laredo, Laredo, Texas. ^[6] University of North Carolina at Chapel Hill. ^[7] University of Chicago, Chicago, Illinois. ^[8] Saint Elizabeth Medical Center South, Edgewood, Kentucky. ^[9] MD Anderson Cancer Center, Houston, Texas. ^[10] Mount Sinai Hospital, New York, New York. ^[11] University of Oklahoma Health Sciences Center, Oklahoma City. ^[12] Mayo Clinic, Rochester, Minnesota. ^[13] Presbyterian Kaseman Hospital, Albuquerque, New Mexico. ^[14] University of Rochester, Rochester, New York. ^[15] Yale School of Medicine, New Hartford, Connecticut. ^[16] Dana-Farber/Partners CancerCare, Boston, Massachusetts. ^[17]

主题词老年人(Aged);女(雌)性(Female);人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);Ki-67抗原(Ki-67 Antigen);肿瘤辅助疗法(Neoadjuvant Therapy);腈类(Nitriles);绝经后期(Postmenopause);受体, 雌激素(Receptors, Estrogen);三唑类(Triazoles);中年人(Middle Aged)

DOI 10.1001/jamaoncol.2023.6038

PMID 38236590

发布时间 2025-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JAMA oncology

2024年10卷3期

362-371页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.

JAMA oncology

相似文献

JAMA oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.

JAMA oncology

相似文献

JAMA oncology

相关期刊

检索历史清除